《业绩》再鼎医药(09688.HK)全年净亏损收窄至2.57亿美元

阿斯达克财经
28 Feb

再鼎医药(09688.HK) 公布2024年度业绩,按美国公认会计准则,总收入3.99亿美元,按年增加49.6%,主要是艾加莫德持续的强劲表现以及则乐和纽再乐销售收入持续增长。经营亏损由3.67亿美元,收窄至2.82亿美元。亏损净额由3.35亿美元,收窄至2.57亿美元,每股亏损26美仙。

过往派息
公布日期派息事项派息内容
2024/11/12第三季业绩无派息
2024/08/07中期业绩无派息
2024/05/09第一季业绩无派息
2024/02/28末期业绩无派息

2025年,全年收入指引介乎5.6亿至5.9亿美元。到2025年第四季度实现非美国公认会计准则经营利润盈利。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-02-27 16:25。)
AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10